A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-29. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
== Tolerance and overdoses == Fatal opioid overdose typically occurs due to bradypnea, hypoxemia, and decreased cardiac output (hypotension occurs due to vasodilation, and bradycardia further contributes to decreased cardiac output). A potentiation effect occurs when opioids are combined with ethanol, benzodiazepines, barbiturates, or other central depressants which can result in rapid loss of consciousness and an increased risk of fatal overdose. Substantial tolerance to respiratory depression develops quickly, and tolerant individuals can withstand larger doses. However, tolerance to respiratory depression is quickly lost during withdrawal and may be completely reversed within a week. Many overdoses occur in people who return to their previous dose after having lost their tolerance following cessation of opioids. This puts addicts who receive medical treatment for opioid addiction at great risk of overdose when they are released, as they may be particularly vulnerable to relapse. Less commonly, massive overdoses have been known to cause circulatory collapse from vasodilation and bradycardia. Opioid overdoses can be rapidly reversed through the use of opioid antagonists, naloxone being the most widely used example. Opioid antagonists work by binding competitively to μ-opioid receptors and displacing opioid agonists. Additional doses of naloxone may be necessary and supportive care should be given to prevent hypoxic brain injury by monitoring vital signs.
German-made Leopard tanks from Warsaw arrived in Ukraine as Polish Prime Minister Mateusz Morawiecki visited Kyiv to send a "clear and measurable signal of further support". The United States authorized $2 billion in aid to Ukraine, and ramped up sanctions and tariffs on Russia. The weapons package announced by the Defense Department included funding for contracts for HIMARS rockets, drones and counter-drone equipment, mine-clearing devices, 155-millimeter artillery ammunition and secure lines of communication. China proposed a peace plan which involves a ceasefire and multiple other steps that would result in direct negotiations. China holds the stance about "countries' sovereignty, independence and territorial integrity be effectively guaranteed" and that the "cold war mentality" should end. US officials such as President Biden and Secretary of State Antony Blinken expressed doubts about the plan, citing doubts over its neutrality and its failure to condemn the invasion. Zelenskyy stated that it was good that China is talking about Ukraine, but that he would cautiously await details on the plan. It was also speculated by some experts that depending on how this turns out, China could also turn around and start supplying Russia with military equipment.
The field of molecular biology grew in the late twentieth century, as did its clinical application. In 1980, Yuet Wai Kan et al. suggested a prenatal genetic test for Thalassemia that did not rely upon DNA sequencing—then in its infancy—but on restriction enzymes that cut DNA where they recognised specific short sequences, creating different lengths of DNA strand depending on which allele (genetic variation) the fetus possessed. In the 1980s, the phrase was used in the names of companies such as Molecular Diagnostics Incorporated and Bethseda Research Laboratories Molecular Diagnostics. During the 1990s, the identification of newly discovered genes and new techniques for DNA sequencing led to the appearance of a distinct field of molecular and genomic laboratory medicine; in 1995, the Association for Molecular Pathology (AMP) was formed to give it structure. In 1999, the AMP co-founded The Journal of Medical Diagnostics. Informa Healthcare launched Expert Reviews in Medical Diagnostics in 2001. From 2002 onwards, the HapMap Project aggregated information on the one-letter genetic differences that recur in the human population—the single nucleotide polymorphisms—and their relationship with disease. In 2012, molecular diagnostic techniques for Thalassemia use genetic hybridization tests to identify the specific single nucleotide polymorphism causing an individual's disease. As the commercial application of molecular diagnostics has become more important, so has the debate about patenting of the genetic discoveries at its heart.
Sources: en.wikipedia.org
=== Neutrinos === The study of beta decay provided the first physical evidence for the existence of the neutrino. In both alpha and gamma decay, the resulting alpha or gamma particle has a narrow energy distribution, since the particle carries the energy from the difference between the initial and final nuclear states. However, the kinetic energy distribution, or spectrum, of beta particles measured by Lise Meitner and Otto Hahn in 1911 and by Jean Danysz in 1913 showed multiple lines on a diffuse background. These measurements offered the first hint that beta particles have a continuous spectrum. In 1914, James Chadwick used a magnetic spectrometer with one of Hans Geiger's new counters to make more accurate measurements which showed that the spectrum was continuous. The results, which appeared to be in contradiction to the law of conservation of energy, were validated by means of calorimetric measurements in 1929 by Lise Meitner and Wilhelm Orthmann. If beta decay were simply electron emission as assumed at the time, then the energy of the emitted electron should have a particular, well-defined value. For beta decay, however, the observed electrons had a broad distribution of energies. A second problem is related to the conservation of angular momentum. Molecular band spectra showed that the nuclear spin of nitrogen-14 is 1 (i.e., equal to the reduced Planck constant) and more generally that the spin is integral for nuclei of even mass number and half-integral for nuclei of odd mass number. This was later explained by the proton-neutron model of the nucleus.
under the joint auspices of the George Washington University and the Carnegie Institution of Washington. There, the news on nuclear fission was spread even further, which fostered many more experimental demonstrations. The 6 January 1939 Hahn and Strassman paper announced the discovery of fission. In their second publication on nuclear fission in February 1939, Hahn and Strassmann used the term Uranspaltung (uranium fission) for the first time, and predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction. The 11 February 1939 paper by Meitner and Frisch compared the process to the division of a liquid drop and estimated the energy released at 200 MeV. The 1 September 1939 paper by Bohr and Wheeler used this liquid drop model to quantify fission details, including the energy released, estimated the cross section for neutron-induced fission, and deduced 235U was the major contributor to that cross section and slow-neutron fission.
== Description and behavior == Bothrops moojeni grows to an average total length (tail included) of 1.6 m (5.2 ft), with a maximum of 2.3 m (7.5 ft) already reported. It has a tan, gray-brown or olive-gray color, with 14–21 trapezoidal side markings that are dark gray or completely black. There are 23–29 rows of dorsal scales on the body. The belly is usually white or cream, with scattered dark gray spots. Juveniles have a white tail. The species is terrestrial and nocturnal. It is considered very defensive. Its body varies from medium to heavy. The broad head is flattened in a lance shape when seen from above, and is distinct from the narrow neck. The snout is not elevated. The eyes are medium in size, with vertically elliptical pupils. The dorsal scales are keeled. B. moojeni is viviparous. Gestation lasts around four months, occurs once a year, and litter size is usually 12–14 neonates. B. moojeni lives an average of 15 years. It preys on small mammals, birds, lizards, snakes and amphibians.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.